Talphera (NASDAQ:TLPH) Upgraded to Strong-Buy at Maxim Group

Maxim Group upgraded shares of Talphera (NASDAQ:TLPH) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Friday, August 16th.

Talphera Stock Performance

Shares of NASDAQ TLPH opened at $0.89 on Friday. The business has a 50 day simple moving average of $0.91 and a 200 day simple moving average of $0.94. The stock has a market cap of $15.12 million, a price-to-earnings ratio of -1.39 and a beta of 0.31. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts predict that Talphera will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Talphera

Large investors have recently added to or reduced their stakes in the business. Turtle Creek Wealth Advisors LLC purchased a new position in Talphera during the 2nd quarter valued at $64,000. Rosalind Advisors Inc. bought a new stake in Talphera in the 3rd quarter worth about $650,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Talphera during the second quarter valued at approximately $1,773,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.